KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ionis Pharmaceuticals (IONS) Debt to Equity (2016 - 2025)

Ionis Pharmaceuticals (IONS) has 17 years of Debt to Equity data on record, last reported at $1.02 in Q3 2025.

  • For Q3 2025, Debt to Equity rose 1421.0% year-over-year to $1.02; the TTM value through Sep 2025 reached $1.02, up 1421.0%, while the annual FY2024 figure was $0.09, 60.4% down from the prior year.
  • Debt to Equity reached $1.02 in Q3 2025 per IONS's latest filing, up from $1.0 in the prior quarter.
  • Across five years, Debt to Equity topped out at $1.02 in Q3 2025 and bottomed at $0.02 in Q1 2023.
  • Average Debt to Equity over 5 years is $0.22, with a median of $0.1 recorded in 2021.
  • The widest YoY moves for Debt to Equity: up 1469.82% in 2021, down 83.48% in 2021.
  • A 5-year view of Debt to Equity shows it stood at $0.08 in 2021, then crashed by 65.97% to $0.03 in 2022, then skyrocketed by 699.23% to $0.22 in 2023, then plummeted by 60.4% to $0.09 in 2024, then soared by 1056.83% to $1.02 in 2025.
  • Per Business Quant database, its latest 3 readings for Debt to Equity were $1.02 in Q3 2025, $1.0 in Q2 2025, and $0.09 in Q4 2024.